# IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

> **NCT00488839** · PHASE3 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 173 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** IPX056 20 mg
- **DRUG:** IPX056 40 mg
- **DRUG:** Encapsulated Baclofen 20 mg
- **DRUG:** Placebo Baclofen Tablet
- **DRUG:** IPX056 10 mg
- **DRUG:** IPX056 30 mg
- **DRUG:** IPX056 35 mg
- **DRUG:** Placebo IPX056 20 mg
- **DRUG:** Placebo IPX056 40 mg

## Key facts

- **NCT ID:** NCT00488839
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488839, "IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00488839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*